---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-010758"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:02:38.470897+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision Q2 revenue $93K, net loss $4.2M; cash only $16K at June 30

## Summary
- Q2 revenue $93K, H1 $175K; net loss Q2 $4.2M, H1 $6.9M.
- Cash at June 30 just $16K; rose to $330K by Aug 12 but remains extremely low.
- First commercial LockeT sales in US: $38K in both Q2 and H1; 23 hospitals scheduling evaluations.
- Total assets $26M, shareholders' equity $14.3M as of June 30.
- 14 new sales/clinical hires; VIVO evaluation started in Italy; VIVO EU Registry completed in June.

## SEC filing metadata
- accession: 0001654954-24-010758
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000165495424010758/0001654954-24-010758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000165495424010758/vtak_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-010758
- JSON: https://secwatch.observer/filing/0001654954-24-010758.json
- Plain text: https://secwatch.observer/filing/0001654954-24-010758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.